Skip to main content
Top
Published in: Clinical & Experimental Metastasis 7/2008

01-11-2008 | Research Paper

Development of a new orthotopic animal model of metastatic liver cancer in the rabbit VX2 model: effect on metastases after partial hepatectomy, intra-arterial treatment with 3-bromopyruvate and chemoembolization

Authors: Josephina A. Vossen, Manon Buijs, Labiq Syed, Fatima Kutiyanwala, Mustafa Kutiyanwala, Jean-Francois H. Geschwind, Mustafa Vali

Published in: Clinical & Experimental Metastasis | Issue 7/2008

Login to get access

Abstract

Aim The aim of our study was to compare the influence of partial hepatectomy, intra-arterial treatment with 3-BrPA and TACE on regional and distant metastases. In order to achieve our objective, we tested the feasibility of both resection, intra-arterial therapy with 3-BrPA and TACE of VX2 liver cancer in New Zealand White rabbits. Methods VX2 tumors were implanted in the left lateral lobe of the liver of 20 rabbits. Tumors were allowed to grow for 14 days. Rabbits were divided in four groups. Group 1 (n = 2) was sacrificed 14 days post implantation. Group 2, 3 and 4 (n = 6) underwent left lateral hepatectomy, a 1 h intra-arterial infusion with 3-BrPA and TACE respectively. Animals in each group were further subdivided into three groups of two animals each corresponding to the time-point of sacrifice after the procedure (7, 14 and 21 days respectively). After sacrifice, organs were harvested, fixed and analyzed. Results Pathologic examination showed lung metastases in all 20 rabbits. Abdominal cavity dissemination was seen in five rabbits in Group 2, two rabbits in Group 3 and all rabbits in Group 4. Kidney metastases were seen in two rabbits treated with TACE. Conclusion The VX2 rabbit model of liver cancer is a suitable model to compare the influence of partial hepatectomy, intra-arterial treatment with 3-BrPA and TACE on tumor recurrence in the form of regional and distant metastases. Our results indicate that intra-arterial delivery of 3-BrPA may result in a favorable metastatic profile when compared to both liver resection and TACE.
Literature
1.
go back to reference Motola-Kuba D, Zamora-Valdes D, Uribe M, Mendez-Sanchez N (2006) Hepatocellular carcinoma: an overview. Ann Hepatol 5:16–24PubMed Motola-Kuba D, Zamora-Valdes D, Uribe M, Mendez-Sanchez N (2006) Hepatocellular carcinoma: an overview. Ann Hepatol 5:16–24PubMed
2.
go back to reference Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, CA: a cancer. J Clin 58:71–96 Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, CA: a cancer. J Clin 58:71–96
3.
go back to reference Leong TY, Leong AS (2005) Epidemiology and carcinogenesis of hepatocellular carcinoma. HPB (Oxford) 7:5–15 Leong TY, Leong AS (2005) Epidemiology and carcinogenesis of hepatocellular carcinoma. HPB (Oxford) 7:5–15
4.
go back to reference Blum HE, Spangenberg HC (2007) Hepatocellular carcinoma: an update. Arch Iran Med 10:361–371PubMed Blum HE, Spangenberg HC (2007) Hepatocellular carcinoma: an update. Arch Iran Med 10:361–371PubMed
7.
go back to reference Zimmerman MA, Ghobrial RM, Tong MJ et al (2008) Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg 143:182–188. Discussion 188. doi:10.1001/archsurg.2007.39 Zimmerman MA, Ghobrial RM, Tong MJ et al (2008) Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg 143:182–188. Discussion 188. doi:10.​1001/​archsurg.​2007.​39
8.
go back to reference Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology (Baltimore, Md.) 35:1164–1171. doi:10.1053/jhep.2002.33156 Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology (Baltimore, Md.) 35:1164–1171. doi:10.​1053/​jhep.​2002.​33156
11.
go back to reference Poon RT, Fan ST, O’Suilleabhain CB, Wong J (2002) Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy. J Am Coll Surg 195:311–318. doi:10.1016/S1072-7515(02)01226-7 PubMedCrossRef Poon RT, Fan ST, O’Suilleabhain CB, Wong J (2002) Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy. J Am Coll Surg 195:311–318. doi:10.​1016/​S1072-7515(02)01226-7 PubMedCrossRef
12.
13.
go back to reference Katyal S, Oliver JH 3rd, Peterson MS, Ferris JV, Carr BS, Baron RL (2000) Extrahepatic metastases of hepatocellular carcinoma. Radiology 216:698–703PubMed Katyal S, Oliver JH 3rd, Peterson MS, Ferris JV, Carr BS, Baron RL (2000) Extrahepatic metastases of hepatocellular carcinoma. Radiology 216:698–703PubMed
14.
go back to reference Vali M, Liapi E, Kowalski J et al (2007) Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer. J Vasc Interv Radiol 18:95–101. doi:10.1016/j.jvir.2006.10.019 PubMedCrossRef Vali M, Liapi E, Kowalski J et al (2007) Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer. J Vasc Interv Radiol 18:95–101. doi:10.​1016/​j.​jvir.​2006.​10.​019 PubMedCrossRef
15.
go back to reference Rous P, Kidd JG, Smith WE (1952) Experiments on the cause of the rabbit carcinomas derived from virus-induced papillomas, II: loss by the Vx2 carcinoma of the power to immunize hosts against the papilloma virus. J Exp Med 96:159–174. doi:10.1084/jem.96.2.159 PubMedCrossRef Rous P, Kidd JG, Smith WE (1952) Experiments on the cause of the rabbit carcinomas derived from virus-induced papillomas, II: loss by the Vx2 carcinoma of the power to immunize hosts against the papilloma virus. J Exp Med 96:159–174. doi:10.​1084/​jem.​96.​2.​159 PubMedCrossRef
17.
go back to reference Phillips PC, Than TT, Cork LC et al (1992) Intrathecal 4-hydroperoxycyclophosphamide: neurotoxicity, cerebrospinal fluid pharmacokinetics, and antitumor activity in a rabbit model of VX2 leptomeningeal carcinomatosis. Cancer Res 52:6168–6174PubMed Phillips PC, Than TT, Cork LC et al (1992) Intrathecal 4-hydroperoxycyclophosphamide: neurotoxicity, cerebrospinal fluid pharmacokinetics, and antitumor activity in a rabbit model of VX2 leptomeningeal carcinomatosis. Cancer Res 52:6168–6174PubMed
21.
go back to reference Peng SY, Lai PL, Pan HW, Hsiao LP, Hsu HC (2008) Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis. Oncol Rep 19:1045–1053PubMed Peng SY, Lai PL, Pan HW, Hsiao LP, Hsu HC (2008) Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis. Oncol Rep 19:1045–1053PubMed
24.
go back to reference Fidler IJ (1995) Critical factors in the biology of human cancer metastasis. Am Surg 61:1065–1066PubMed Fidler IJ (1995) Critical factors in the biology of human cancer metastasis. Am Surg 61:1065–1066PubMed
26.
go back to reference Vali M, Vossen J, Buijs M et al (2008) Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study. J Pharmacol Exp Ther Vali M, Vossen J, Buijs M et al (2008) Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study. J Pharmacol Exp Ther
Metadata
Title
Development of a new orthotopic animal model of metastatic liver cancer in the rabbit VX2 model: effect on metastases after partial hepatectomy, intra-arterial treatment with 3-bromopyruvate and chemoembolization
Authors
Josephina A. Vossen
Manon Buijs
Labiq Syed
Fatima Kutiyanwala
Mustafa Kutiyanwala
Jean-Francois H. Geschwind
Mustafa Vali
Publication date
01-11-2008
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 7/2008
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-008-9195-x

Other articles of this Issue 7/2008

Clinical & Experimental Metastasis 7/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine